{"filings":[{"id":920037,"accession_number":"0001193125-26-261965","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2026-06-08T20:54:11+00:00","items":["5.07"],"status":"ready","headline":"NeuroPace reports 2026 annual meeting voting results; directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Lisa Andrade and Scott Huennekens elected as Class II directors to serve until 2029 annual meeting.","PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year ending December 31, 2026.","Director election had 8,048,133 broker non-votes; auditor ratification had none."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40284,"accession_number":"0001528287-26-000019","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2026-05-12T20:07:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace Q1 RNS rev $21.7M (+19.5%); raises FY26 rev guidance to $99-101M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["RNS System revenue $21.7M (+19.5% YoY); total revenue $22.1M including $0.1M DIXI Medical.","GAAP net loss $6.7M; Adjusted EBITDA loss ex DIXI improved to $3.3M from $4.1M YoY.","Cash $54.8M vs $61.2M prior quarter; long-term debt $59M.","FY2026 revenue guidance raised to $99-101M (from $98-100M), representing 21-23% RNS growth.","Expects IGE indication expansion contribution after potential NAUTILUS PMA-S approval mid-2026."],"consensus_eps_estimate":-0.2346,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":22068000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105072,"accession_number":"0001528287-26-000008","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace Q4 rev $26.6M (+24%), FY25 rev $100M (+25%); guides FY26 $98-100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $26.6M (+24% YoY); RNS System revenue $22.4M (+26% YoY); gross margin 77.4%.","Full year 2025 revenue $100.0M (+25% YoY); net loss ($2.7M) Q4; Adj. EBITDA ($5.0M) FY25.","Submitted PMA-S to FDA for IGE indication expansion; NAUTILUS trial showed 77% median seizure reduction.","Reiterated FY26 guidance: total rev $98-100M (20-22% RNS growth); Adj. EBITDA ($9-10M).","DIXI Medical partnership ended Dec 31, 2025; discontinued ops reporting to begin Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121323,"accession_number":"0001528287-25-000030","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace reports record Q3 revenue $27.4M (+30% YoY); raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue of $27.4M, up 30% YoY; RNS System revenue $22.6M (+31% YoY).","Gross margin expanded to 77.4% from 73.2% YoY; operating loss narrowed to $2.6M from $4.2M.","Net loss improved to $3.5M from $5.5M YoY; cash and short-term investments $60M.","Raised FY2025 revenue guidance to $97M-$98M (21-23% YoY growth) and gross margin to 76%-77%.","On track to submit NAUTILUS PMA supplement to FDA for IGE indication expansion by year-end 2025."],"consensus_eps_estimate":-0.2002,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":73398000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137978,"accession_number":"0001528287-25-000021","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace posts Q2 revenue $23.5M (+22% YoY); raises FY2025 revenue and margin guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue grew 22% YoY to $23.5M; RNS System revenue up 16% in Q2.","Full-year 2025 revenue guidance raised to $94-98M (previous $93-97M).","Gross margin 77.1% in Q2; FY margin guidance increased to 75-76%.","Net loss $8.7M vs $7.5M; free cash flow improved to ($2.3M).","NAUTILUS IGE study missed primary endpoint but showed 79% GTC seizure reduction at 12 months."],"consensus_eps_estimate":-0.227,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":46044000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155371,"accession_number":"0001193125-25-145738","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeuroPace names Patrick Williams as CFO; Rebecca Kuhn departs after 25 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rebecca Kuhn stepped down as CFO on June 20, 2025; will serve as Senior Strategic Advisor through June 19, 2026.","Kuhn receives 12 months base salary severance, 18 months COBRA, $88,885 pro-rated bonus, and continued equity vesting.","Patrick F. Williams appointed CFO effective June 20; previously CFO at STAAR Surgical (2024 net sales >$300M).","Williams' base salary $500,000, target bonus 60%, plus equity awards: 51,850 RSUs and 87,950 options with 4-year vest.","CEO Joel Becker noted Williams' experience scaling medical device companies; thanked Kuhn for 25-year tenure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155370,"accession_number":"0001193125-25-139896","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NeuroPace stockholders re-elect directors Becker and Fischer, ratify PwC as auditor for FY2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Joel Becker re-elected with ~19.7M votes for (99.4%); broker non-votes 7.7M.","Frank Fischer re-elected with ~14.7M votes for (74.1%); broker non-votes 7.7M.","Ratification of PwC as independent auditor for FY2025 approved with ~27.5M votes for (99.7%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155369,"accession_number":"0001193125-25-134946","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"NeuroPace secures $75M credit facility, refinances existing $60M term loan with MidCap","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $60M term loan and $15M revolver mature June 4, 2030; proceeds repaid $61.9M to CRG.","Interest: SOFR +5.5% (term) and SOFR +3.75% (revolver), both with 2% floor.","Financial covenant: min liquidity $25M; revenue target of $90M in 2026 can ease covenant levels.","Prepayment premiums: 3% (year 1), 2% (year 2), 1% (year 3), 0% thereafter.","Company says new facility reduces cash interest expense and provides non-dilutive growth capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155368,"accession_number":"0001193125-25-126268","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NeuroPace NAUTILUS study meets safety endpoint; primary efficacy miss but significant in subgroup","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary safety endpoint met: low rate of serious adverse events related to device/implant procedure.","Primary efficacy endpoint (time to second GTC seizure) not statistically significant in overall population.","Statistically significant response in subgroup with lower baseline GTC seizure frequency, representing majority of participants.","Secondary metrics (median seizure reduction, responder rates, seizure-free days) showed clinically meaningful improvements.","Full-year 2025 financial guidance reaffirmed; CEO notes base business growing >20% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155367,"accession_number":"0001528287-25-000012","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace reports record Q1 revenue $22.5M (+24% YoY), raises FY2025 guidance to $93-97M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue $22.5M, up 24% YoY; RNS System revenue up 29% excluding NAUTILUS study implants.","Gross margin 77.0% exceeded full-year guidance of 73-75%; operating loss narrowed to $5.1M from $7.5M.","Full-year 2025 revenue guidance raised to $93-97M (16-21% growth); expects NAUTILUS topline data in H2 2025.","Strategic refocus on core RNS System; terminating SEEG distribution relationship starting Q4 2025 through Q1 2026.","Cash and investments $66.3M; long-term debt $59.8M as of March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":22524000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155366,"accession_number":"0001193125-25-080217","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeuroPace sees minimal tariff impact, reaffirms 2025 gross margin guidance","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Expects minimal impact from international trade tariffs on operations and financial results.","Reaffirmed gross margin guidance for fiscal year 2025; no material impact on margins.","Q1 2025 earnings results to be reported after market close on May 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155365,"accession_number":"0001193125-25-071399","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NeuroPace drops SEEG distribution deal to focus on core RNS System; reaffirms 2025 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated exclusive DIXI Medical SEEG distribution; wind down begins Q4 2025 through Q1 2026.","CEO cites strategic refocus on RNS System; expects growth from Project CARE, indication expansions, AI software.","Maintaining 2025 revenue guidance; no change to long-range plan of 20%+ CAGR and cash flow breakeven by end of 2027.","Gross margin expected to improve: SEEG margin ~50% vs. RNS margin >78%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173884,"accession_number":"0001528287-25-000006","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace reports Q4 revenue $21.5M (+19% YoY); guides FY2025 revenue $92-96M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $21.5M (+19% YoY); full year revenue $79.9M (+22%).","Net loss improved: Q4 $5.3M (vs $6.2M); full year $27.1M (vs $33.0M).","FY2025 guidance: revenue $92-96M (15-20% growth), gross margin 73-75%, operating expenses $92-95M.","Completed $74.8M public offering; used $49.5M to repurchase 5.3M shares from KCK Ltd.; pro forma cash $68.6M.","NAUTILUS study completes March 2025; FDA submission H2 2025; NEST pediatric program for indication expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173883,"accession_number":"0001193125-25-030729","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NeuroPace completes repurchase of 5.27M shares from KCK Ltd., terminates ATM program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased 5,270,845 shares of common stock from KCK Ltd., allowing an organized sale of KCK's entire stake.","Funded repurchase using a portion of proceeds from recent underwritten public offering.","Company expects sufficient cash runway to achieve cash flow breakeven.","Terminated existing ATM equity offering program with $38.3M remaining capacity.","CEO thanks KCK for support; believes balance sheet supports long-range plan from investor day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173882,"accession_number":"0001193125-25-028174","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NeuroPace announces public offering of 6.5M shares at $10; to repurchase $49.5M in shares from KCK","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offers 6,500,000 shares at $10.00 per share; net proceeds expected ~$60.6M.","Will use $49.5M of net proceeds to repurchase 5,270,845 shares from KCK Ltd. at $9.40/share.","Underwriters granted 30-day option to purchase up to 975,000 additional shares.","Closing expected February 18, 2025; remaining proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173881,"accession_number":"0001193125-25-026573","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NeuroPace to repurchase 17.5% stake from KCK at equity offering price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreed to repurchase all shares held by KCK, representing ~17.5% of outstanding common stock.","Repurchase price equals the price per share in the concurrent underwritten equity offering.","Closing conditioned on completion of equity offering; expected no earlier than 2 business days after.","Transaction approved by audit and pricing committees of independent directors.","Repurchased shares will become authorized but unissued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173880,"accession_number":"0001193125-25-014473","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"NeuroPace issues 2025 revenue guidance $92M-$96M; 3-year CAGR target 20%+","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 revenue guidance $92M-$96M (15.5%-20.5% YoY growth); gross margin 73%-75%; total OpEx $92M-$95M.","Three-year targets: 20%+ revenue CAGR, indication expansion to IGE/pediatric, AI tools, and cash flow breakeven.","Post-approval trial: 82% median seizure reduction at 36 months (n=255); 42.5% seizure-free ≥6 months; 22% ≥1 year.","NAUTILUS trial (IGE): 87 patients implanted; 1-yr follow-up due by March 2025; data lock Q2 2025; FDA submission H2 2025.","Plans to release first AI-powered electrographic seizure classifier tool within RNS System PDMS in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173879,"accession_number":"0001193125-25-007085","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"NeuroPace to present at J.P. Morgan Healthcare Conference; no financial updates","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation at 43rd Annual J.P. Morgan Healthcare Conference on Jan 15, 2025 at 4:30 p.m. PT.","Materials will be posted on NeuroPace investor site at investors.neuropace.com/news-and-events/events.","No material new information or financial guidance disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173878,"accession_number":"0001193125-25-003547","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"NeuroPace Reports Preliminary 2024 Revenue Above Guidance and Appoints Scott Huennekens to Board","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited Q4 2024 revenue expected $21.0M-$21.5M (17-19% growth vs Q4 2023), full year $79.4M-$79.9M (21-22% growth), above initial guidance of $73M-$77M.","Cash and short-term investments as of Dec 31, 2024 expected $52.8M; shares outstanding 30,145,039.","Scott Huennekens appointed to Board of Directors effective Jan 6, 2025; granted options for 15,507 shares at $11.93.","NAUTILUS trial one-year follow-up on track for March 2025; data lock and analysis in Q2 2025.","Management to present at J.P. Morgan Healthcare Conference Jan 15 and host Investor Day Jan 28 in NYC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":79906000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190850,"accession_number":"0001528287-24-000019","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace Q3 revenue $21.1M (+28% YoY); raises FY2024 guidance to $78-80M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue $21.1M vs $16.4M Q3 2023, driven by RNS System sales.","Net loss narrowed to $5.5M ($0.22 EPS) from $7.3M; operating loss $4.2M vs $6.0M.","Cash burn reduced to $1.8M from $2.3M; cash & investments $56.8M at quarter end.","Full-year 2024 revenue guidance raised to $78-80M (19-22% growth); gross margin guided 72-74%.","Appointed Brett Wingeier VP R&D, Katie Keller VP Marketing, Amy Treadwell VP HR."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":58440000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207331,"accession_number":"0001528287-24-000015","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace Q2 revenue $19.3M (+17% YoY); raises FY2024 guidance to $76-78M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $19.3M (17% YoY) vs $16.5M; net loss $7.5M vs $9.1M prior year.","Gross margin expanded to 73.4% from 72.5%; operating loss narrowed to $6.2M.","Cash burn improved to $4.0M; cash & investments $55.5M; long-term debt $59.0M.","FY2024 revenue guidance raised to $76-78M (16-19% growth); gross margin 72-74%.","Operating expenses $20.4M; R&D $6.1M, SG&A $14.3M; cash burn reduction noted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":37380000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224737,"accession_number":"0001193125-24-158459","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NeuroPace stockholders elect three Class III directors and ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Uri Geiger elected with 10,710,133 for, 363,203 withheld, 7,926,126 broker non-votes.","Rakhi Kumar elected with 10,629,853 for, 443,483 withheld.","Renee Ryan elected with 9,556,538 for, 1,516,798 withheld.","Ratification of PricewaterhouseCoopers LLP as auditor: 18,989,774 for, 9,305 against, 383 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224736,"accession_number":"0001528287-24-000010","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"NeuroPace Q1 revenue $18.1M (+25% YoY), net loss $8.9M; loan maturity extended to Sept 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $18.1M vs $14.5M in Q1 2023, driven by RNS System and DIXI Medical sales.","Net loss $8.9M, improved from $10.4M; operating loss $7.5M vs $8.3M.","Cash burn $7.6M, down from $9.8M; cash & investments $58.9M; debt $58.0M.","Term loan maturity extended one year to Sept 30, 2026; PIK interest option shortened.","FY2024 guidance reaffirmed: revenue $73-77M, gross margin 72-74%, opex $80-84M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":18124000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244008,"accession_number":"0001528287-24-000004","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace reports record 2023 revenue $65.4M (+44% YoY); guides 2024 revenue $73M-$77M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record FY 2023 revenue $65.4M (+44% YoY); Q4 revenue $18.0M (+41% YoY). Net loss improved to $33.0M from $47.1M.","Gross margin improved to 73.6% (FY) from 71.4%; Q4 75.2% vs 68.8%. Cash burn reduced to $3.4M in Q4.","FY 2024 guidance: revenue $73M-$77M (+12-18%), gross margin 72-74%, operating expenses $80M-$84M.","NAUTILUS study for generalized epilepsy completed enrollment and implants for FDA submission; Project CARE pilot initiated.","Cash position $66.5M, long-term debt $57.0M; stock-based comp ~$9.6M in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244007,"accession_number":"0001193125-24-026756","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NeuroPace Chief Legal Officer Irina Ridley resigns; transition agreement with consulting and severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Irina Ridley resigns as CLO and Corporate Secretary; last day of employment is March 6, 2024.","Transition Agreement provides base salary, benefits, and vesting through Separation Date; 2023 bonus eligible.","Post-separation consulting period through Dec 31, 2024; initial stock option continues vesting.","Severance includes 12 months base salary continuation and up to 12 months COBRA reimbursement.","One-time cash payment of $32,226 upon signing general release of claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244006,"accession_number":"0001193125-24-003861","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NeuroPace preliminary Q4 rev $17.5-18.0M (+37-41% YoY); NAUTILUS trial completed early","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2023 revenue $17.5-18.0M, up 37-41% YoY; full year 2023 revenue $64.9-65.4M, up 43-44% YoY, well above initial guidance of $50-52M.","Cash and short-term investments $66.5M as of Dec 31, 2023, including $7.9M from ATM and portion of data collaboration proceeds.","Completed enrolling and implanting patients required for FDA submission in NAUTILUS pivotal trial for idiopathic generalized epilepsy more than a quarter early.","Initial milestones achieved in first strategic data collaboration with a biotech company; expects up to $3.7M in total proceeds over nine quarters.","Project CARE pilot to expand RNS System access to community setting on track for 1H 2024 launch; centers already implanting patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261414,"accession_number":"0001193125-23-288474","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NeuroPace enters $3.7M collaboration with Rapport for Phase 2a trial of RAP compound","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Rapport Therapeutics to support Phase 2a trial of GAMA 8 Receptor-Associated Protein (RAP) compound.","NeuroPace provides site data and monitoring capabilities for RNS System patients enrolled in the trial.","Agreement spans nine quarters (Q4 2023 to Q4 2025) with milestones, subject to early termination provisions.","Total anticipated revenue from collaboration is approximately $3.7 million, including a trial initiation payment in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261413,"accession_number":"0001528287-23-000040","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace Q3 revenue $16.4M (+47% YoY), raises FY2023 guidance to $62.5-$63.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $16.4M (+47% YoY); net loss $7.3M vs $11.8M a year ago.","Cash burn reduced to $2.2M in Q3, down from $4M in Q2 and $9.8M in Q1.","Full-year revenue guidance raised to $62.5-$63.5M (prev $59-$61M); gross margin guided 71%-73%.","FDA approved Tablet Remote Monitor; launched nSight platform. NAUTILUS trial enrollment on track for Q1 2024.","First RNS implants in community setting under Project CARE; sufficient cash to fund operations into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":47409000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278649,"accession_number":"0001528287-23-000033","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace Q2 revenue $16.5M (+62% YoY); raises FY 2023 guidance to $59-61M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $16.5M, up 62% YoY and 14% QoQ; net loss narrowed to $9.1M from $12.7M YoY.","Full-year 2023 revenue guidance raised to $59-61M (30-34% growth), from prior $52-54M.","Cash burn reduced to $4M in Q2 from $9.8M in Q1; cash and investments $63.6M at June 30.","NAUTILUS trial enrollment on track; full enrollment expected Q1 2024 for generalized epilepsy.","Gross margin 72.5%; operating expenses flat YoY; DIXI product distribution contributed to revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":30982000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278648,"accession_number":"0001193125-23-189608","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeuroPace grants CEO Joel Becker option for 380,424 shares as inducement to join","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation Committee approved 2023 Inducement Plan reserving 380,424 shares for awards to new employees.","Granted Joel Becker an option to purchase 380,424 shares as material inducement for him to become CEO.","Plan is substantially similar to 2021 Equity Incentive Plan but prohibits ISOs and limits awards to eligible new hires per Nasdaq rules.","Inducement Plan adopted without stockholder approval under Nasdaq Listing Rule 5635(c)(4).","Effective date of plan and grant: July 18, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296869,"accession_number":"0001193125-23-177492","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeuroPace CEO Michael Favet resigns; Joel Becker appointed as new CEO effective July 10, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Favet resigns as CEO and Board member effective July 10, 2023; will provide consulting services for 12 months at $600/hour.","Joel Becker appointed President and CEO effective July 10, 2023; also joins Board as Class I director through 2025 annual meeting.","Becker receives base salary of $520,000/year, target bonus of 75% of salary, and option grant of 380,424 shares vesting over 4 years.","Becker most recently served as President at Viking North Ventures; prior roles include Integer Holdings and St. Jude Medical.","Favet's unvested equity awards will be cancelled on August 1, 2023; vested options remain exercisable per award agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296868,"accession_number":"0001528287-23-000028","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NeuroPace stockholders elect two Class II directors, ratify PwC as auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Lisa Andrade (8,506,611 for, 432,292 withhold) and Joseph Lacob (8,475,094 for, 463,809 withhold) as Class II directors until 2026.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2023: 16,456,369 for, 9,012 against, 11,989 abstain.","Broker non-votes of 7,538,467 on director election; no broker non-votes on auditor ratification.","No other matters were submitted for stockholder action at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296867,"accession_number":"0001528287-23-000024","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace Q1 revenue $14.5M (+27% YoY) and raises FY2023 guidance to $52-54M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $14.5M, up 27% YoY and 13% sequentially; net loss narrowed to $10.4M from $11.5M.","Full-year 2023 revenue guidance raised to $52-54M (prior $50-52M), implying 14-19% YoY growth.","Gross margin 72% vs 73% YoY; operating expenses $18.7M; cash and investments $67.6M.","RNS System utilization and DIXI Medical distribution drove growth; replacement implants declined.","NAUTILUS pivotal study for primary generalized epilepsy enrolling as expected."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":14472000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296866,"accession_number":"0001193125-23-100628","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NeuroPace director Greg Garfield will not seek reelection; Board to shrink to seven","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Greg Garfield informed NeuroPace on April 11, 2023 he will not stand for reelection as director.","Garfield's departure is not due to any disagreements with NeuroPace's operations, policies or practices.","Board intends to reduce size from eight to seven directors effective as of the Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317227,"accession_number":"0001528287-23-000005","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace Q4 revenue $12.8M (+16% YoY); guides FY2023 revenue $50-52M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $12.8M (+16% YoY); initial implant revenue $9.8M (+15% YoY).","Full year 2022 revenue $45.5M (+1% YoY); net loss $47.1M vs $36.1M in 2021.","FY2023 guidance: revenue $50-52M (10-14% growth), gross margin 69-71%, op expenses $75-77M.","DIXI Medical distribution contributed $1.6M in Q4; NAUTILUS study for primary generalized epilepsy ongoing.","Cash burn reduced to ~$15M in H2 2022 from ~$23M in H1; cash $77.4M at year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317226,"accession_number":"0001193125-23-004750","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"NeuroPace reports Q4 2022 preliminary revenue $12.8M (+16% YoY); appoints Dr. Uri Geiger to board","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 total revenue expected ~$12.8M, up 16% from $11.0M in Q4 2021; initial implant revenue $9.8M (+15%).","Full-year 2022 revenue expected ~$45.5M, flat vs $45.2M in 2021; initial implant revenue $35.7M (+6%).","Dr. Uri Geiger, founder of Accelmed Partners, appointed to Board effective Jan 5, 2023; granted option for 120,521 shares at $1.535.","Replacement implant revenue declined 44% in Q4 ($1.4M) and 29% for FY2022 ($8.2M); DIXI Medical contributed $1.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":45520000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335507,"accession_number":"0001528287-22-000026","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace Q3 revenue $11.2M (+8% YoY); lifts FY revenue guidance to $44.5-45.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Initial implant revenue $9.2M (+18% YoY); replacement revenue $1.9M vs $2.5M prior year.","Net loss $11.8M vs $8.1M prior year; operating expenses $18.2M vs $13.8M.","Cash and equivalents $85.4M, down from $92.4M at June 30; long-term debt $52.0M.","Gross margin 71% vs 73% due to short-term supply chain disruption, now resolved.","Initiated distribution of DIXI Medical stereo EEG electrodes on Oct 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":32731000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352923,"accession_number":"0001528287-22-000017","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"NeuroPace Q2 revenue $10.2M (-19% YoY); net loss $12.7M; signs exclusive DIXI Medical SEEG distribution deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $10.2M vs $12.6M YoY; initial implant revenue $8.0M, replacement $2.2M.","Net loss $12.7M vs $8.5M YoY; operating expenses $18.4M up from $14.0M.","FY 2022 guidance: total revenue $43-45M, initial implant $34-36M; DIXI Medical revenue ~$1.5M in Q4.","Signed exclusive 3-year U.S. distribution deal for DIXI Medical SEEG electrodes; total payments of $4.5M.","Cash and equivalents $92.4M, down from $103.2M at March 31; long-term borrowings $51.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":21574000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370545,"accession_number":"0001193125-22-176557","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NeuroPace stockholders elect Favet, Fischer to board; ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael Favet re-elected with 14,886,315 votes for, 1,376,600 withheld.","Frank Fischer re-elected with 14,476,168 votes for, 1,786,747 withheld.","Ratification of PricewaterhouseCoopers as auditor for FY2022: 22,756,875 for, 1,498 against, 2,521 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370544,"accession_number":"0001528287-22-000011","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace Q1 revenue $11.4M, net loss widens to $11.5M; guides FY2022 revenue $45-48M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $11.4M (+2% YoY); initial implant rev $8.8M (+9%); replacement rev $2.6M (-16%).","Net loss widened to $11.5M from $8.8M; operating expenses $18.0M vs $12.4M.","Gross margin 73% vs 76% due to higher costs and COVID disruptions; cash $103.2M.","FY2022 guidance: revenue $45-48M, initial implants $39-42M, opex $74-76M.","On track to enroll first patients in NAUTILUS trial for generalized epilepsy expansion mid-2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":11374000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389623,"accession_number":"0001528287-22-000004","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace reports 2021 revenue $45.2M (+10% YoY), Q4 net loss $10.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year initial implant revenue $33.7M (+20% YoY); replacement revenue $11.5M (-12% YoY).","Q4 total revenue $11.0M (+2% YoY); net loss $10.7M vs $4.6M loss in Q4 2020.","FDA approved IDE for pivotal study in drug-resistant primary generalized epilepsy.","2022 guidance: full-year revenue $45-48M, initial implant revenue $39-42M.","Cash and marketable securities $115.6M; long-term borrowings $49.8M as of Dec 31, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389622,"accession_number":"0001193125-22-006746","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2022-01-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NeuroPace reports preliminary Q4 2021 revenue of $11.0M (+2% YoY); FY2021 $45.2M (+10% YoY)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2021 revenue ~$11.0M (+2% YoY); initial implant $8.5M (+10%), replacement $2.5M (-19%).","FY2021 revenue ~$45.2M (+10% YoY); initial implant $33.7M (+20%), replacement $11.5M (-12%).","150 centers performed RNS implant in 2021, up 14% from 132 centers in 2020.","Enrolled first patient in adolescent study to expand indications beyond current pool.","Full Q4 and FY results expected in mid-March 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407571,"accession_number":"0001528287-21-000017","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace Q3 revenue drops 19% to $10.3M; net loss widens to $8.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $10.3M down 19% YoY; initial implant revenue $7.8M down 15%.","Net loss $8.1M vs $4.1M loss in prior year; gross margin 72.6% vs 75.0%.","Updated FY2021 guidance: total revenue $44-44.5M (7-8% growth), initial implant $33-33.5M.","Received IDE approval for clinical study to expand indication to primary generalized epilepsy.","Added Lisa Andrade to Board; submitted PMA supplement for longer battery life claim (nearly 11 yrs)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":34186000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407570,"accession_number":"0001193125-21-302022","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2021-10-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NeuroPace appoints Lisa Andrade as Class II director, replacing Evan Norton","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Evan Norton resigned as Class II director effective Nov 1, 2021; no disagreement cited.","Lisa Andrade appointed as Class II director effective Nov 1, 2021, term through 2023 annual meeting.","Andrade will serve on Audit and Compensation Committees.","She receives a stock option with $185K grant-date fair value, monthly vesting over 3 years.","Annual cash retainers: $40K board, $10K audit, $7,500 compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426598,"accession_number":"0001528287-21-000013","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2021-09-09T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"NeuroPace warns Q3 revenue uncertainty due to COVID-19 Delta variant procedure delays","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Procedure volumes impacted in Q3 due to scheduling delays from COVID-19 Delta variant.","Management believes delays will create uncertainty around revenue for second half of 2021.","Company to participate in three healthcare conferences: Wells Fargo, Morgan Stanley, Baird."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426597,"accession_number":"0001528287-21-000009","cik":1528287,"company_name":"NeuroPace Inc","ticker":"NPCE","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroPace Q2 revenue $12.6M (+65% YoY); initial implants up 100%; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $12.6M (+65% YoY); initial implant revenue $9.2M (+100% YoY, +14% QoQ).","Net loss $8.5M vs $8.8M; cash $127.9M; long-term debt $49.4M.","Reaffirmed FY2021 guidance: total revenue ~$47M, initial implant ~$36M.","Received up to $9.3M NIH BRAIN grant to evaluate RNS System for Lennox-Gastaut Syndrome.","Plans to start enrolling adolescent epilepsy patients before year-end; IDE for primary generalized epilepsy in 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":23847000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":585389603.9648302,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}